Catheter ablation is an
evolving therapeutic strategy for the management of atrial fibrillation (AF).
It is associated with a risk of thromboembolic events. The peri-procedural anticoagulation
management with warfarin has been successful in mitigating this risk. However,
introduction of novel oral anticoagulants like dabigatran offers more
flexibility in anticoagulation approaches.
Previous studies had evaluated the safety and efficacy of dabigatran in the
radiofrequency ablation, but data related to cryoballoon ablation is lacking.
performed a retrospective observational study involving patients who underwent
cryoballoon ablation for drug-refractory, symptomatic AF while on dabigatran in
periprocedural period. Thromboembolic, hemorrhagic or other complications
occurring within the first 30 days after the ablation procedure were analyzed.
study population comprised of 50 patients with mean age of 58.96 ± 3.54 years with 76% (n=38) being male. We
found 3 (6%) minor complications in peri-procedural period including 2 groin
hematomas and 1 trace asymptomatic pericardial effusion. There were no major
intraprocedural or post procedural hemorrhagic or thromboembolic events. None of patients with the minor complications
required significant additional workup or extended hospital stay. All the
patients were able to continue dabigatran for 30 days without any additional
side effects or complications.
Dabigatran is a safe and
efficacious agent in patients undergoing cryoballoon AF ablation.
Credits: Valay Parikh, M.D.; Vratika Agarwal, M.B.B.S.; Jharendra Rijal, M.B.B.S.; Vinod Chainani, M.D.; Soad Bekheit, M.D., Ph.D. FHRS; Marcin Kowalski, M.D.FACC, FHRS